Trevi Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Trevi Therapeutics (TRVI) PT Lowered to $8 at Needham & Company
November 11, 2021 6:47 AM ESTNeedham & Company analyst Serge Belanger lowered the price target on Trevi Therapeutics (NASDAQ: TRVI) to $8.00 (from $10.00) while maintaining a Buy rating.
The analyst commented, "TRVI reported 3Q21 financials and provided a corporate update. The ph 2b/3 PRISM trial, evaluating Haduvio (nalbuphine ER) as... More
